European Guidelines Now Recommend Semaglutide and Tirzepatide for Fatty Liver Disease Management | Research

The takeaway

The joint EASL-EASD-EASO clinical practice guidelines for metabolic fatty liver disease (MASLD) recommend incretin-based therapies like semaglutide and tirzepatide as part of optimal management for patients with coexisting diabetes or obesity.

3-society guideline
EASL, EASD, and EASO jointly recommend incretin peptide therapies for MASLD patients with diabetes or obesity

What the researchers found

The guidelines establish a comprehensive framework for MASLD management with several key recommendations:

- Case-finding using non-invasive tests (FIB-4 score, then transient elastography) in patients with cardiometabolic risk factors

- Lifestyle modification as the foundation: weight loss, dietary changes, exercise, no alcohol

- Incretin-based therapies (semaglutide, tirzepatide) recommended for optimal management of comorbidities in MASLD patients with type 2 diabetes or obesity

- Resmetirom recommended as MASH-targeted treatment for non-cirrhotic patients with significant fibrosis (stage ≥2)

- Bariatric surgery as an option for MASLD patients with obesity

- No MASH-targeted pharmacotherapy recommended for cirrhotic stage

Why it matters

This is a landmark guideline that formally positions incretin-based peptide therapies as part of standard MASLD management — a significant expansion beyond their original diabetes and obesity indications. With MASLD affecting an estimated 30% of the global adult population, the explicit recommendation of semaglutide and tirzepatide in these guidelines will drive widespread prescribing and may accelerate dedicated clinical trials for liver-specific outcomes with these peptide drugs.

How the study worked

This is a joint clinical practice guideline from three European medical societies: EASL (liver), EASD (diabetes), and EASO (obesity). The guideline was developed through systematic evidence review and expert consensus, providing graded recommendations for prevention, screening, diagnosis, and treatment of MASLD.

What this study cannot tell us

As guidelines rather than original research, these recommendations are limited by the evidence available at the time of writing. The liver-specific outcomes of semaglutide and tirzepatide in MASLD are still being studied in dedicated trials — the recommendation is based largely on their metabolic benefits. Resmetirom is the only specifically liver-targeted drug recommended, and only for non-cirrhotic patients. Implementation may vary widely based on local healthcare resources and drug availability.

How to read the evidence

Clinical practice guidelines represent the highest level of synthesized evidence, integrating systematic reviews and expert consensus. These are joint guidelines from Europe's leading liver, diabetes, and obesity societies, carrying substantial clinical authority.

When this study was published

Published in 2024, these are the current authoritative European guidelines for MASLD management, incorporating the latest evidence on both incretin therapies and resmetirom.

The bigger picture

These guidelines mark a convergence of hepatology, diabetology, and obesity medicine around a shared disease entity. The recommendation of GLP-1 receptor agonists and GIP/GLP-1 dual agonists for MASLD reflects the growing understanding that metabolic liver disease is inseparable from systemic cardiometabolic dysfunction. This is one of the most significant guideline endorsements for incretin-based peptide therapies outside of their core diabetes and obesity indications.

Questions still open

Will dedicated MASLD outcome trials for semaglutide and tirzepatide show direct liver fibrosis improvement beyond metabolic benefits?
How should clinicians prioritize between incretin-based therapies and resmetirom in patients who qualify for both?
Will these guidelines accelerate regulatory approval of GLP-1 agonists for MASLD as a standalone indication?

Common questions

What is MASLD and why did the name change from NAFLD?

MASLD (metabolic dysfunction-associated steatotic liver disease) is the new name for what was previously called NAFLD (non-alcoholic fatty liver disease). The name was changed because the old term defined the disease by what it isn't (non-alcoholic) rather than what it is (metabolic). MASLD is fat buildup in the liver caused by metabolic factors like obesity, diabetes, and high cholesterol, and it can progress to liver scarring, cirrhosis, and liver cancer.

Why are diabetes drugs being recommended for liver disease?

MASLD is fundamentally a metabolic disease — it's driven by the same factors that cause diabetes and obesity (insulin resistance, excess fat, inflammation). Drugs like semaglutide and tirzepatide improve these underlying metabolic problems, leading to weight loss, better insulin sensitivity, and reduced liver fat. While they weren't originally developed for liver disease, their metabolic benefits directly address what drives MASLD, which is why these guidelines recommend them.

Read the original research

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.

Diabetologia, 67(11), 2375-2392

View on PubMed ↗Publisher’s paper ↗

Citation

. (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.. Diabetologia, 67(11), 2375-2392. https://doi.org/10.1007/s00125-024-06196-3